Back
Novavax 10K Form
Sell
32
NVAX
Novavax
Last Price:
18.20
Seasonality Move:
4.4%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-08-10 | 10Q | NVAX/Novavax Quarterly |
| 2020-05-11 | 10Q | NVAX/Novavax Quarterly |
| 2020-04-29 | 10K | NVAX/Novavax Annual |
| 2020-03-11 | 10K | NVAX/Novavax Annual |
| 2019-11-07 | 10Q | NVAX/Novavax Quarterly |
| 2019-08-07 | 10Q | NVAX/Novavax Quarterly |
Receive NVAX News And Ratings
See the #1 stock for the next 7 days that we like better than NVAX
NVAX Financial Statistics
Sales & Book Value
| Annual Sales: | $1.15B |
|---|---|
| Cash Flow: | $-195.48M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-5.33 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -19.46000 |
|---|---|
| Net Income (TTM): | $-1.48B |
| Gross Margin: | $0 |
| Return on Equity: | -1465.25% |
| Return on Assets: | -55.27% |
Novavax Earnings Forecast
Key Novavax Financial Ratios
- The Gross Profit Margin over the past 21 years for NVAX is 0.00%.
- The Selling, General & Administrative Expenses for NVAX have been equal to 26.03% of Gross Profit Margin.
- The Research & Development expenses have been 221.11% of Revenue.
- The Interest Expense is -1.21% of Operating Income.
- The Net Earning history of NVAX is -152.12% of Total Revenues.
- Per Share Earnings over the last 26 years have been positive in 11 years.
Novavax Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Current Symbol: | NVAX |
| CUSIP: | 670002 |
| Website: | novavax.com |
Debt
| Debt-to-Equity Ratio: | -0.78 |
|---|---|
| Current Ratio: | 0.99 |
| Quick Ratio: | 0.73 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 2.7 |